Default company panoramic image
Square 20logo


We are developing novel immune activating leukemia therapeutics.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Philadelphia, PA, US
  • Currency USD
  • Founded February 2017
  • Employees 1
  • Incorporation Type C-corp
  • Website

Company Summary

Diffregen is developing Angiocidin and a new class of therapeutics that provide a novel approach for activating the immune system against cancer. In healthy monocytes, Angiocidin leads to immune stimulating cytokine release and macrophage differentiation; in leukemia cells, this induces terminal differentiation and blocks growth. Angiocidin shows great potential as a breakthrough therapeutic for Acute Myeloid Leukemia.